LIFECORE BIOMEDICAL, INC. \DE\
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Income taxes
- Income taxes
The Company recorded income tax expense on pre-tax losses in all periods presented, resulting in negative effective tax rates. The effective tax rates were negative rates of less than 1% and approximately 3% for the three months ended September 30, 2026 and 2025, respectively, and negative rates of less than 1% and approximately 2% for the nine months ended September 30, 2026 and 2025, respectively. The effective tax rates were lower than the U.S. federal statutory tax rate in all periods primarily due to the Company’s valuation allowance on its deferred tax assets.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.